Table 8 VAS score at 3, 6, 12, and 24-month follow-up
Authors (Year, level of evidence) | No of patients in the accelerated group (AG) and conservative group (CG)a | VAS score (mean ± standard deviation) | |||
|---|---|---|---|---|---|
3-month follow-up | 6-month follow-up | 12-month follow-up | 24-month follow-up | ||
Jenssen et al. [73] (2018, I) | AG (60) | - | - | 8.6 ± 1.8 | - |
CG (58) | - | - | 8.7 ± 1.9 | - | |
Keener et al. [63] (2014, I) | AG (61) | - | 1.4 ± 1.6 | 1.1 ± 1.7 | 0.9 ± 1.7 |
CG (53) | - | 1.1 ± 1.4 | 0.9 ± 1.2 | 0.6 ± 1.1 | |
Kim et al. [64] (2012, I) | AG (56) | - | 3 | 2.8 | - |
CG (49) | - | 3.2 | 1.8 | - | |
Klintberg et al. [72] (2009, II) | AG (7) | 2.5 ± 0.5 | 1.2 ± 0.8 | 0 | 0.8 ± 0.9 |
CG (7) | 2.4 ± 1.7 | 0.3 ± 0.5 | 0.9 ± 1.1 | 0.3 ± 0.4 | |
Koh et al. [77] (2014, I) | AG (40) | - | 2.7 ± 1.5 | - | 1.3 ± 1.8 |
CG (48) | - | 2.7 ± 1.8 | - | 0.8 ± 1.0 | |
Lee et al. [67] (2012, II) | AG (30) | - | - | 0.9 ± 0.9 | - |
CG (34) | - | - | 0.8 ± 0.9 | - | |
Mazzocca et al. [68] (2017, II) | AG (31) | 1.6 ± 1.4 | 1.0 ± 1.7 | 0.7 ± 1.5 | - |
CG (27) | 2.7 ± 2.3 | 1.4 ± 2.3 | 0.9 ± 1.5 | - | |
Raschhofer et al. [69] (2017, II) | AG (14) | 1.9 ± 0.7 | 0.4 ± 0.4 | - | - |
CG (15) | 2 ± 0.8 | 0.1 ± 0.5 | - | - | |
Sheps et al. [78] (2015, II) | AG (97) | 1.4 ± 1.6 | 0.8 ± 1.3 | 0.5 ± 0.8 | 0.4 ± 0.9 |
CG (92) | 1.3 ± 1.6 | 0.9 ± 1.6 | 0.9 ± 1.7 | 0.5 ± 1.3 | |
Sheps et al. [79] (2019, I) | AG (103) | 1.8 ± 2.1 | 0.9 ± 1.3 | 0.6 ± 1.0 | 0.7 ± 1.3 |
CG (103) | 1.4 ± 1.6 | 0.8 ± 1.0 | 0.6 ± 1.0 | 0.6 ± 1.3 | |
Tirefort et al. [80] (2019, I) | AG (40) | 1.9 ± 1.9 | 0.8 ± 1.1 | - | - |
CG (40) | 2.6 ± 2.1 | 1.5 ± 1.6 | - | - | |